About epcoritamab
CD3×CD20 bispecific antibody
Used for
- Treats certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments.
- Treats certain adults with relapsed or refractory follicular lymphoma after at least two prior treatments.
Usual adult dose
Under the skin in step-up doses, then 48 mg weekly for lymphoma; schedule changes over time and depends on indication.
Common side effects
- Cytokine release syndrome, including fever, low blood pressure, and breathing problems
- Low blood cell counts and infections
- Injection-site reactions, fatigue, and fever
- Immune effector cell-associated neurotoxicity, including confusion or seizures
Important warnings
- Cytokine release syndrome and neurological toxicity can be severe or life-threatening; treatment requires close monitoring.
- Serious infections and low blood counts may occur.
- Step-up dosing and prescribed premedication help reduce treatment risks.
- Avoid live vaccines during treatment and until immune recovery.
Pregnancy
May harm an unborn baby. Pregnancy status is assessed before treatment; effective contraception is advised during treatment and for four months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for four months after the last dose.
Interactions
- Medicines that affect immune function may alter treatment effects.
- Epcoritamab can change levels of some medicines by altering inflammatory signals; review narrow-therapeutic-index drugs.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.